This week, I take another look at venture capital (VC) investments in genomics. As suggested by Daniel, I ask which VCs invested in a panel of representative genomics companies, and what these investments looked like.
The result: The most active VCs in genomics are Alloy, Google Ventures, and Mohr Davidow, which each invested in three genomics companies from the panel. They are followed by InterWest, Invus, and OrbiMed, which each invested in two.
On average, the companies in the panel raised a total of $32m from four different investors in three funding rounds. The median individual investment was $5.8m. The median investment per round was $11.7m, which is twice the 2001-2010 VC industry average of $5.9m per round.
The panel for the above analysis consists of all those genomics companies that I mentioned on this blog in the last few months: 23andMe, BioNano, Complete Genomics, DNAnexus, Fluidigm, Foundation Medicine, GenomeQuest, Good Start Genetics, Nabsys, Natera, Oxford Nanopore, PathoGenetix, PrimeraDx, RainDance, and Verinata.
For each company, I checked which VCs invested in it using Crunchbase. Not included are companies that have gone public, did not receive VC money, or for which no data is available on Crunchbase.
Having assembled this panel, I am wondering how I could improve it and which other interesting questions I could address with it. Any suggestions?